← Back to Screener
Stevanato Group S.p.A. (STVN)
Price$15.86
Favorite Metrics
Price vs S&P 500 (26W)-38.85%
Price vs S&P 500 (4W)-0.98%
Market Capitalization$5.10B
P/E Ratio (Annual)26.32x
Indicated Dividend Yield (Annual)0.39%
All Metrics
P/CF (Annual)12.87x
Book Value / Share (Quarterly)$6.41
P/TBV (Annual)3.22x
Indicated Dividend (Annual)$0.07
Revenue Growth (3Y)6.44%
Cash Flow / Share (Quarterly)$0.05
Payout Ratio (TTM)18.07%
Price vs S&P 500 (YTD)-25.10%
Gross Margin (TTM)29.60%
Net Profit Margin (TTM)11.79%
EPS (TTM)$0.60
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$0.60
Revenue Growth (5Y)12.37%
EPS (Annual)$0.60
Dividend / Share (Annual)$0.06
ROI (Annual)7.15%
Gross Margin (Annual)29.60%
Net Profit Margin (5Y Avg)13.26%
Cash / Share (Quarterly)$0.56
P/E Basic Excl Extra (TTM)26.32x
Revenue Growth QoQ (YoY)4.81%
EPS Growth (5Y)13.98%
P/E Normalized (Annual)26.32x
ROA (Last FY)5.50%
Revenue Growth TTM (YoY)7.45%
EBITD / Share (TTM)$0.91
ROE (5Y Avg)12.19%
Operating Margin (TTM)16.76%
Cash Flow / Share (Annual)$0.05
P/B Ratio2.48x
P/B Ratio (Quarterly)3.14x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.39x
Net Interest Coverage (TTM)20.90x
ROA (TTM)5.81%
EPS Growth QoQ (YoY)-0.91%
EV / EBITDA (TTM)19.03x
EPS Incl Extra (Annual)$0.60
Current Ratio (Annual)1.76x
Quick Ratio (Quarterly)1.26x
3-Month Avg Trading Volume0.60M
52-Week Price Return-27.45%
EV / Free Cash Flow (Annual)363.88x
P/E Incl Extra (TTM)26.32x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.25
P/S Ratio (Annual)3.10x
Asset Turnover (Annual)0.47x
52-Week High$28.00
Operating Margin (5Y Avg)17.73%
EPS Excl Extra (Annual)$0.60
CapEx CAGR (5Y)23.43%
26-Week Price Return-31.96%
Quick Ratio (Annual)1.26x
13-Week Price Return-24.48%
Total Debt / Equity (Annual)0.32x
Current Ratio (Quarterly)1.76x
Enterprise Value$4,734.159
Revenue / Share Growth (5Y)14.12%
Asset Turnover (TTM)0.49x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.25x
Pretax Margin (Annual)15.94%
Cash / Share (Annual)$0.56
3-Month Return Std Dev64.42%
Gross Margin (5Y Avg)31.00%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)14.02%
EBITDA Interim CAGR (5Y)12.26%
ROE (Last FY)9.41%
Net Interest Coverage (Annual)16.31x
EPS Basic Excl Extra (Annual)$0.60
P/FCF (TTM)131.22x
Receivables Turnover (TTM)2.50x
EV / Free Cash Flow (TTM)363.88x
Total Debt / Equity (Quarterly)0.32x
EPS Incl Extra (TTM)$0.60
Receivables Turnover (Annual)2.44x
ROI (TTM)7.49%
P/S Ratio (TTM)3.10x
Pretax Margin (5Y Avg)17.33%
Revenue / Share (Annual)$5.12
Tangible BV / Share (Annual)$6.25
Forward P/E22.25x
Free OCF CAGR (5Y)-28.64%
Price vs S&P 500 (52W)-62.08%
P/E Ratio (TTM)26.32x
EPS Growth TTM (YoY)18.04%
Year-to-Date Return-21.17%
5-Day Price Return7.38%
EPS Normalized (Annual)$0.60
ROA (5Y Avg)7.13%
Net Profit Margin (Annual)11.79%
Month-to-Date Return15.35%
Cash Flow / Share (TTM)$1.06
EBITD / Share (Annual)$0.91
EPS Growth (3Y)-1.71%
Operating Margin (Annual)16.76%
LT Debt / Equity (Annual)0.23x
P/CF (TTM)12.87x
ROI (5Y Avg)8.81%
P/E Excl Extra (TTM)26.32x
LT Debt / Equity (Quarterly)0.23x
EPS Basic Excl Extra (TTM)$0.60
P/TBV (Quarterly)3.22x
Payout Ratio (Annual)10.54%
P/B Ratio (Annual)3.14x
Dividend / Share (TTM)$0.06
Inventory Turnover (TTM)3.25x
Pretax Margin (TTM)15.94%
Book Value / Share (Annual)$6.41
Price vs S&P 500 (13W)-26.86%
Net Margin Growth (5Y)-0.12%
Dividend Yield (TTM)0.40%
Beta0.66x
P/FCF (Annual)333.25x
Revenue / Share (TTM)$5.12
ROE (TTM)9.75%
52-Week Low$12.89
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.18
4.18
4.18
4.18
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
STVNStevanato Group S.p.A. | 3.10x | 12.37% | 29.60% | 16.76% | $15.86 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Stevanato Group provides integrated drug containment, delivery, and diagnostic solutions throughout the pharmaceutical and biotechnology industries' product life cycles, spanning development, clinical, and commercial stages. The company operates through two segments: Biopharmaceutical and Diagnostic Solutions, which generates the majority of revenue, and Engineering. Stevanato derives most of its revenue from Europe, the Middle East, and Africa.